A038290 Stock Overview
Macrogen, Inc. provides precision medicine and bio-engineering healthcare services in Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Macrogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩19,890.00 |
| 52 Week High | ₩29,900.00 |
| 52 Week Low | ₩15,470.00 |
| Beta | -0.025 |
| 1 Month Change | -15.18% |
| 3 Month Change | -10.61% |
| 1 Year Change | 3.06% |
| 3 Year Change | -39.17% |
| 5 Year Change | -39.27% |
| Change since IPO | -9.86% |
Recent News & Updates
Shareholder Returns
| A038290 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0.6% | -0.5% | -0.4% |
| 1Y | 3.1% | 2.2% | 4.5% |
Return vs Industry: A038290 matched the KR Life Sciences industry which returned 2.9% over the past year.
Return vs Market: A038290 underperformed the KR Market which returned 7.1% over the past year.
Price Volatility
| A038290 volatility | |
|---|---|
| A038290 Average Weekly Movement | 4.7% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A038290 has not had significant price volatility in the past 3 months.
Volatility Over Time: A038290's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 532 | Changhoon Kim | www.macrogen.com |
Macrogen, Inc. provides precision medicine and bio-engineering healthcare services in Korea and internationally. It offers personal healthcare services, including disease prediction and wellness genetic, and DTC genetic testing services; MyPETGENE, a genetic testing service for companion animals; clinical services, such as precision medicine, genetic testing for cancer risk, NGS-based genetic panel lab, and GCLP services; and single cell expert services comprising single cell multi-omics and spatial transcriptome analysis, and single cell (In Situ/spatial) services. The company also provides whole genome, whole exome, transcriptome, epigenome, and metagenome sequencing services; standard sequencing, identification, fragment, customized sequencing, and human ID services; expression, genome, and epigenome microarray; proteomics olink; gene synthesis; DNA and RNA oligo synthesis, and peptide synthesis; and CRISPR knock-in/out, GEM, and mass production services.
Macrogen, Inc. Fundamentals Summary
| A038290 fundamental statistics | |
|---|---|
| Market cap | ₩198.48b |
| Earnings (TTM) | -₩16.81b |
| Revenue (TTM) | ₩132.80b |
1.5x
P/S Ratio-11.8x
P/E RatioIs A038290 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A038290 income statement (TTM) | |
|---|---|
| Revenue | ₩132.80b |
| Cost of Revenue | ₩83.56b |
| Gross Profit | ₩49.24b |
| Other Expenses | ₩66.05b |
| Earnings | -₩16.81b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68k |
| Gross Margin | 37.08% |
| Net Profit Margin | -12.66% |
| Debt/Equity Ratio | 22.8% |
How did A038290 perform over the long term?
See historical performance and comparison